Home / Business and Economy / Greggs Faces Investor Doubts Amid Diet Drug Boom
Greggs Faces Investor Doubts Amid Diet Drug Boom
1 Mar
Summary
- Short positions on Greggs shares exceed 13.2 percent.
- Weight-loss drugs are cited as a major concern for sales.
- Expected profit for 2025 shows a decline from the prior year.
Traders are increasingly betting against the Greggs bakery chain, with short positions now representing over 13.2 percent of its shares, making it the most-shorted stock in London as of March 1, 2026. This significant bearish sentiment stems from growing concerns about the impact of popular weight-loss drugs, such as Mounjaro and Ozempic, on the company's future sales.
Greggs is anticipated to announce a profit of £170 million for the year 2025, a notable decrease from the £204 million reported the previous year. Boss Roisin Currie has acknowledged that consumers are shifting towards smaller portion sizes and are more focused on nutritional content like protein and fiber, signaling a potential challenge for the company's traditional product offerings.
